Evidence map›Paper›PMID 33241064›Full record

ArticleOpen forum infectious diseases2020

In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant

Donna Carr, Zufei Zhang, Qian Si, Fred Racine, Jing Chen Xiao, Ravi Katwaru, Michael K Wismer, Matthew G Johnson, Hwa-Ping Feng, Katherine Young and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 68% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Donna CarrMerck & Co., Inc., Kenilworth, New Jersey, USA.
Zufei ZhangMerck & Co., Inc., Kenilworth, New Jersey, USA.
Qian SiMerck & Co., Inc., Kenilworth, New Jersey, USA.
Fred RacineMerck & Co., Inc., Kenilworth, New Jersey, USA.
Jing Chen XiaoMerck & Co., Inc., Kenilworth, New Jersey, USA.
Ravi KatwaruMerck & Co., Inc., Kenilworth, New Jersey, USA.
Michael K WismerMerck & Co., Inc., Kenilworth, New Jersey, USA.
Matthew G JohnsonMerck & Co., Inc., Kenilworth, New Jersey, USA.
Hwa-Ping FengMerck & Co., Inc., Kenilworth, New Jersey, USA.
Katherine YoungMerck & Co., Inc., Kenilworth, New Jersey, USA.
Matthew L RizkMerck & Co., Inc., Kenilworth, New Jersey, USA.
Mary MotylMerck & Co., Inc., Kenilworth, New Jersey, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our hollow-fiber infection model simulated the projected steady-state pharmacokinetics of ceftolozane and tazobactam in lung epithelial lining fluid of patients with pneumonia receiving 3 g of ceftolozane/tazobactam every 8 hours. Results confirmed the previously established in vitro activity of ceftolozane/tazobactam at and above approved breakpoints against multidrug-resistant

Indexed as

antibacterial resistancehollow-fiber infection modelpharmacokinetics/pharmacodynamicsPseudomonas aeruginosa

Identifiers

PMID33241064
PMCPMC7672432
OpenAlexW3092486057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.